GAITHERSBURG, Md., May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Thursday, May 11, 2023 | |||||
Time: | 10:00 – 10:30 a.m. Pacific Daylight Time (PDT) | |||||
Location: | Encore Hotel in Las Vegas, Nevada | |||||
Moderator: | Alec Stranahan, Ph.D., Equity Research Analyst – Biotechnology | |||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, May 10, 2023 - Thursday, May 11, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined.
Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz | 240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan or Giovanna Chandler | 240-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.40 |
| Daily Change: | -0.15 -1.99 |
| Daily Volume: | 3,814,881 |
| Market Cap: | US$1.200B |
May 19, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
